Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.
The clinical trial matching app, which Roche collaborated on with MolecularMatch, is the latest in a series of features that it will introduce in its tumor board solution.
ScienceInsider reports that universities may be worse than drug companies at reporting clinical trial results.
The Associated Press reports on early, potentially promising results from a gene-editing trial.
US companies have begun recruiting for a CRISPR-based gene-editing trial to treat β-thalassemia, Stat News reports.
Priorities for Q3 include the continued buildup of a commercial launch for the company's BarreGEN test. The firm has started a second clinical validation study for the test.
Researchers in Japan being a new trial of induced pluripotent stem cells to treat Parkinson's disease, Science reports.
Stat News reports federal regulators have halted Sarepta Therapeutics' Duchenne muscular dystrophy gene therapy trial.
With the new five-year funding, patients across Australia with rare or less common cancers will be able to access the program through a network of eight cancer centers.
Collaborators said that the test is accurate and reliable for the rapid detection of the most common gram-positive bacteria responsible for bloodstream infections.
Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.
The Wall Street Journal looks into the cost of new gene therapies.
An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.
In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.